Mirum Pharmaceuticals, Inc.

MIRM

US6047491013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
24.46 ^USD	-0.12%		+2.73%	-17.14%

Apr. 17	Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	MT
Apr. 02	Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	CI

Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024

February 28, 2024 at 04:30 pm EST

Mirum Pharmaceuticals, Inc. provided sales guidance for the year 2024. The company expects net product sales to be $310 million to $320 million for 2024.

Latest news about Mirum Pharmaceuticals, Inc.

Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	Apr. 17	MT
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	Apr. 02	CI
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating	Mar. 14	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Mar. 14	MT
Sector Update: Health Care	Mar. 14	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating	Mar. 14	MT
Mirum Pharmaceuticals Says FDA Approved Familial Intrahepatic Cholestasis Treatment	Mar. 14	MT
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli	Mar. 13	DJ
US FDA approves expanded use of Mirum's liver disease drug	Mar. 13	RE
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis	Mar. 13	CI
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating	Mar. 04	MT
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024	Feb. 28	CI
Transcript : Mirum Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M	Feb. 28	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Mirum Pharmaceuticals, Inc. Announces Management Changes	Jan. 16	CI
Mirum Pharmaceuticals Names Joanne Quan as Chief Medical Officer	Jan. 16	MT
Mirum Pharmaceuticals, Inc. Announces Management Appointments	Jan. 16	CI
Transcript : Mirum Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	Jan. 10
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023	Jan. 08	CI
Raymond James Cuts Price Target on Mirum Pharmaceuticals to $64 From $78, Keeps Strong Buy Rating	Dec. 19	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 18	MT
Sector Update: Health Care Stocks Rising Monday Afternoon	Dec. 18	MT
Mirum Pharmaceuticals Shares Fall After Disappointing Data From Phase 2B Study for Biliary Atresia	Dec. 18	MT
Mirum Pharma's liver disease therapy fails in mid-stage study	Dec. 18	RE

Chart Mirum Pharmaceuticals, Inc.

Duration

Period

More charts

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Mirum Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.46 USD

Average target price

48.91 USD

Spread / Average Target

+99.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIRUM PHARMACEUTICALS, INC.	-17.14%	1.15B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research